Viatris Inc. (VTRS)
| Market Cap | 12.07B |
| Revenue (ttm) | 14.12B |
| Net Income (ttm) | -3.47B |
| Shares Out | 1.17B |
| EPS (ttm) | -2.92 |
| PE Ratio | n/a |
| Forward PE | 4.39 |
| Dividend | $0.48 (4.64%) |
| Ex-Dividend Date | Aug 22, 2025 |
| Volume | 5,038,595 |
| Open | 10.36 |
| Previous Close | 10.31 |
| Day's Range | 10.34 - 10.50 |
| 52-Week Range | 6.85 - 13.55 |
| Beta | 0.89 |
| Analysts | Hold |
| Price Target | 11.17 (+7.92%) |
| Earnings Date | Nov 6, 2025 |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price target is $11.17, which is an increase of 7.92% from the latest price.
News
Teva Vs. Viatris: Who Will Dominate In President Trump's America?
Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA...
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
Strengthens Viatris' Presence in Japan With the Addition of Two Innovative Assets Targeting Areas of Significant Unmet Medical Need Leverages Existing Infrastructure and Expertise in Central Nervous S...
Viatris to Participate in Upcoming Investor Conferences
PITTSBURGH , Oct. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in Novembe...
Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs
Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deli...
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
PITTSBURGH , Oct. 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2025. This is the f...
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025
PITTSBURGH , Oct. 1, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m...
Viatris: Indore Plant Could Boost 2026 Numbers
Viatris continues to struggle with declining sales across all regions, with Q2-2025 net sales down 7% year over year. VTRS's Indore plant issues have significantly impacted results, but a full recover...
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
PITTSBURGH , Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Offic...
Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers
Many high-yield S&P 500 stocks are risky, but 19 'safer' dividend dogs have strong free cash flow to support payouts and are worth considering. Analyst forecasts suggest the top ten S&P 500 dividend d...
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths...
Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript
Viatris Inc. (NASDAQ:VTRS) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andr...
Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise
Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business Positive Results From Five Phase 3 Data Readouts This Year Rei...
Viatris Announces Quarterly Dividend
PITTSBURGH , Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 4, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued an...
Viatris Announces Appointment of David Simmons to the Company's Board of Directors
PITTSBURGH , Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that David Simmons has been appointed as the newest member of Viatris' Board of Dire...
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH , Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTR...
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. VTRS on Friday announced topline data from a Phase 3 study evaluating the effic...
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target
The pharmaceutical company says its eye inflammation treatment didn't meet its target.
Viatris eye therapy fails to meet late-stage trial goal
Viatris said on Friday that its experimental ophthalmic ointment did not meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
PITTSBURGH , July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the...
Viatris: A Contrarian Bet With Virtually No Downside
Viatris has aggressively deleveraged, now poised for growth with a robust pipeline and global presence in key markets like the US, India, and China. The company's balance sheet is much improved, divid...
Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys
High-yield S&P 500 stocks can be risky, but 14 "safer" S&P 500 dividend dogs have strong free cash flow to support payouts and are attractive buys. Analyst forecasts suggest top ten S&P 500 dividend d...
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinica...
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
PITTSBURGH , June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m...
